CD274 and breast cancer: However, although at present, some clinical data support a good effect of the anti-PD-L1 immunotherapy, alone or in combination with BCG, in BC patients [77,78,79], no conclusive evidence of the predictive role of cancer’s PD-L1 levels in the anti-PD-1/PD-L1 immunotherapy outcome have been reported yet [32,80].